Cargando…

Anti-tumor necrosis factor therapy in inflammatory bowel disease

Detalles Bibliográficos
Autor principal:	Ramakrishna, B.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Book Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663180/ http://dx.doi.org/10.4103/0971-5916.213765

Ejemplares similares

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy
por: Shim, Tae Sun
Publicado: (2014)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
por: Nawaz, Ahmad, et al.
Publicado: (2023)

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
por: Gareb, Bahez, et al.
Publicado: (2020)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
por: Lee, Ko Eun, et al.
Publicado: (2019)

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
por: Lee, Jang Wook, et al.
Publicado: (2016)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Overcoming challenges in IBD management
por: Ramakrishna, B.S.
Publicado: (2015)

How gut and brain control metabolism
por: Ramakrishna, B.S.
Publicado: (2016)

Therapy of Inflammatory Bowel Disease. New Medical and Surgical Approaches
por: Levine, Jimmy
Publicado: (1990)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications
por: Kang, Elise, et al.
Publicado: (2018)

Leukocytoclastic Vasculitis Secondary to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases: A Multicenter Retrospective Cohort Study
por: Parra, Rogério Serafim, et al.
Publicado: (2023)

High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy
por: Likhitsup, Alisa, et al.
Publicado: (2019)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Innovative Concepts in Inflammatory Bowel Diseases
por: Watson, Peter
Publicado: (1999)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease
por: Yau, Tung On, et al.
Publicado: (2022)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease
por: Ślebioda, Tomasz J., et al.
Publicado: (2014)

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease
por: Bordalo Ferreira, Filipa, et al.
Publicado: (2023)

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
por: Na, Soo-Young, et al.
Publicado: (2022)

Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
por: Wang, Liang-Fang, et al.
Publicado: (2023)

Inflammatory bowel diseases: Microbiota versus the barrier
por: Desai, Devendra
Publicado: (2015)

Relation between Selected Sleep Parameters, Depression, Anti-Tumor Necrosis Factor Therapy, and the Brain-Derived Neurotrophic Factor Pathway in Inflammatory Bowel Disease
por: Sochal, Marcin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pj87thj86uusi5boghv4utlk4k